LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling Corrigendum in /10.3892/ijo.2019.4769 Corrigendum in /10.3892/ijo.2022.5305

Xiao,Qungen; Dong,Minhai; Cheng,Fangling; Mao,Feng; Zong,Weifeng; Wu,Kang; Wang,Heping; Xie,Ruifan; Wang,Baofeng; Lei,Ting; Guo,Dongsheng

doi:10.3892/ijo.2018.4482

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling

Corrigendum in: /10.3892/ijo.2019.4769 Corrigendum in: /10.3892/ijo.2022.5305

Authors:
- Qungen Xiao
- Minhai Dong
- Fangling Cheng
- Feng Mao
- Weifeng Zong
- Kang Wu
- Heping Wang
- Ruifan Xie
- Baofeng Wang
- Ting Lei
- Dongsheng Guo
View Affiliations

Affiliations: Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: July 16, 2018 https://doi.org/10.3892/ijo.2018.4482
Pages: 1069-1082
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The leucine‑rich repeats and immunoglobulin‑like domains (LRIG) gene family, comprising LRIG1, 2 and 3, encodes integral membrane proteins. It has been well established that LRIG1 negatively regulates multiple growth factor signaling pathways and is considered to be a tumor suppressor; however, the biological functions of LRIG2 remain largely unexplored. It was previously demonstrated that LRIG2 positively regulates epidermal growth factor receptor (EGFR) signaling, the most common aberrant receptor tyrosine kinase (RTK) signaling in glioblastoma multiforme (GBM), which promotes GBM growth. In the present study, the effect of LRIG2 on the proliferation of GBM cells was further addressed, as well as the possible mechanisms underlying the regulatory effect of LRIG2 on platelet‑derived growth factor receptor β (PDGFRβ) signaling, another common oncogenic RTK signaling pathway in GBM. First, the expression levels of endogenous LRIG2 and PDGFRβ were found to vary notably in human GBM, and the LRIG2 expression level was positively correlated with the expression level of PDGFRβ. Furthermore, to the best of our knowledge, this is the first study to demonstrate that LRIG2 promoted the PDGF‑BB‑induced proliferation of GBM cells in vitro and in vivo through regulating the PDGFRβ signaling‑mediated cell cycle progression. Mechanistically, LRIG2 has the ability to physically interact with PDGFRβ, promoting the total expression and the activation of PDGFRβ, and enhancing its downstream signaling pathways of Akt and signal transducer and activator of transcription 3 and the effectors of key regulators of cell cycle progression, resulting in increased GBM cell proliferation. Collectively, these data indicated that LRIG2 may serve as a tumor promoter gene in gliomagenesis by positively regulating PDGFRβ signaling, another important oncogenic RTK signaling pathway, in addition to the previously reported EGFR signaling in GBM modulated by LRIG2, and validated LRIG2 as a promising therapeutic target for the treatment of GBM characterized by multiple aberrant RTK signaling.

View Figures

View References

1	Wen PY and Reardon DA: Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
2	Patel M, Vogelbaum MA, Barnett GH, Jalali R and Ahluwalia MS: Molecular targeted therapy in recurrent glioblastoma: Current challenges and future directions. Expert Opin Investig Drugs. 21:1247–1266. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
4	Paulsson J, Lindh MB, Jarvius M, Puputti M, Nistér M, Nupponen NN, Paulus W, Söderberg O, Dresemann G, von Deimling A, et al: Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer. 128:1981–1988. 2011. View Article : Google Scholar
5	Guo D, Holmlund C, Henriksson R and Hedman H: The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics. 84:157–165. 2004. View Article : Google Scholar : PubMed/NCBI
6	Simion C, Cedano-Prieto ME and Sweeney C: The LRIG family: Enigmatic regulators of growth factor receptor signaling. Endocr Relat Cancer. 21:R431–R443. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004. View Article : Google Scholar : PubMed/NCBI
8	Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL III and Sweeney C: LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol. 27:1934–1946. 2007. View Article : Google Scholar :
9	Ledda F, Bieraugel O, Fard SS, Vilar M and Paratcha G: Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer. 18:312–317. 2008. View Article : Google Scholar
11	Hellberg D, Tot T and Stendahl U: Pitfalls in immunohistochemical validation of tumor marker expression - exemplified in invasive cancer of the uterine cervix. Gynecol Oncol. 112:235–240. 2009. View Article : Google Scholar
12	Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, et al: Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res. 9:1406–1417. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Poulin EJ and Coffey RJ: LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer. 108:1765–1770. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, Chen CM, Chan C, Chao SC, et al: LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene. 33:1375–1384. 2014. View Article : Google Scholar
15	Ranhem C, Lillsunde Larsson G, Hedman H, Lindquist D, Karlsson MG, Hellström AC, Östensson E, Sorbe B, Hellman K and Andersson S: Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma. PLoS One. 12:e01838162017. View Article : Google Scholar : PubMed/NCBI
16	Rouam S, Moreau T and Broët P: Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes. BMC Bioinformatics. 11:1502010. View Article : Google Scholar : PubMed/NCBI
17	Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
18	Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, Henriksson R and Hedman H: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology. 29:242–247. 2009. View Article : Google Scholar
19	Hedman H, Lindström AK, Tot T, Stendahl U, Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol. 49:812–815. 2010. View Article : Google Scholar : PubMed/NCBI
20	Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, Henriksson R and Hedman H: Lrig2-deficient mice are protected against PDGFB-induced glioma. PLoS One. 8:e736352013. View Article : Google Scholar : PubMed/NCBI
21	Wang B, Han L, Chen R, Cai M, Han F, Lei T and Guo D: Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther. 8:1018–1023. 2009. View Article : Google Scholar : PubMed/NCBI
22	Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie R, Wang B, Lei T and Guo D: Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. PLoS One. 9:e1114192014. View Article : Google Scholar : PubMed/NCBI
23	Mao F, Wang B, Xiao Q, Xi G, Sun W, Zhang H, Ye F, Wan F, Guo D, Lei T, et al: A role for LRIG1 in the regulation of malignant glioma aggressiveness. Int J Oncol. 42:1081–1087. 2013. View Article : Google Scholar : PubMed/NCBI
24	Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye F, Wan F, Wang B, Lei T and Guo D: Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep. 29:177–184. 2013. View Article : Google Scholar
25	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
26	Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R and Hedman H: Characterization and tissue-specific expression of human LRIG2. Gene. 332:35–43. 2004. View Article : Google Scholar : PubMed/NCBI
27	Andrae J, Gallini R and Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
28	Nazarenko I, Hede SM, He X, Hedrén A, Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
29	Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV and Hamada J: Aberrant signaling pathways in glioma. Cancers (Basel). 3:3242–3278. 2011. View Article : Google Scholar
30	Paradowski M, Bilinska M and Bar J: Characteristics of the expression of KAI1/CD82 and PDGFRβ and their impact on glioma progression. Folia Neuropathol. 54:241–248. 2016. View Article : Google Scholar
31	Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 25:55–57. 2000. View Article : Google Scholar : PubMed/NCBI
32	Brantley EC and Benveniste EN: Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol Cancer Res. 6:675–684. 2008. View Article : Google Scholar : PubMed/NCBI
33	Reardon DA, Wen PY and Mellinghoff IK: Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 16(Suppl 8): viii7–13. 2014. View Article : Google Scholar : PubMed/NCBI
34	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
35	Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817. 2011. View Article : Google Scholar : PubMed/NCBI
36	Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL III and Sweeney C: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 279:47050–47056. 2004. View Article : Google Scholar : PubMed/NCBI